Prescription weight loss medications are appropriate clinical tools for women with a BMI of 30 or higher, or BMI of 27 or higher with weight-related health conditions including type 2 diabetes, hypertension, dyslipidemia, PCOS, or obstructive sleep apnea, for whom lifestyle modification alone has not achieved adequate results. They are not shortcuts or cosmetic interventions — they are medications that address specific biological mechanisms that impair weight loss in susceptible individuals, with demonstrated effects on weight-related health outcomes including diabetes prevention, cardiovascular risk reduction, and improvement in PCOS symptoms.
GLP-1 Receptor Agonists — The Transformative Class
GLP-1 (glucagon-like peptide-1) receptor agonists are the most effective prescription weight loss medications currently available. Semaglutide (Ozempic for diabetes, Wegovy for weight loss) and liraglutide (Victoza for diabetes, Saxenda for weight loss) mimic the GLP-1 hormone produced by the gut after eating, producing reduced appetite, increased satiety, slowed gastric emptying, and reduced food intake. Clinical trials of semaglutide for weight loss show average weight loss of 15 to 18 percent of body weight — approaching the weight loss achievable with bariatric surgery for some patients. Tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) adds GIP receptor agonism alongside GLP-1 and produces even greater weight loss in clinical trials, averaging 20 to 22 percent. These medications have transformed the medical weight loss landscape because their efficacy substantially exceeds all prior weight loss medications. They also produce significant improvements in insulin resistance, lipid profiles, blood pressure, and cardiovascular risk — making them particularly appropriate for women with PCOS, insulin resistance, and perimenopausal metabolic syndrome.
Metformin — Insulin Sensitization and Modest Weight Support
Metformin is not a primary weight loss medication but produces modest weight loss as a secondary effect of its insulin-sensitizing action in women with PCOS and insulin resistance. It is the first-line medication for PCOS management and for diabetes prevention in women with prediabetes. For PCOS-related weight management in particular, metformin addresses the primary metabolic driver of weight gain and supports the dietary and lifestyle changes that produce weight loss in this population.
Other FDA-Approved Weight Loss Medications
Phentermine-topiramate ER (Qsymia), bupropion-naltrexone (Contrave), and orlistat (Xenical/Alli) are FDA-approved for chronic weight management in appropriate candidates. These medications produce modest to moderate weight loss (5 to 10 percent of body weight on average) and have different side effect profiles and mechanisms. They may be appropriate when GLP-1 medications are not covered by insurance, not tolerated, or contraindicated.
Integration With Hormonal Management
Medical weight loss medications and hormonal management are complementary rather than competing approaches for perimenopausal women with both hormonal and weight-related health concerns. Hormone therapy addresses the estrogen-deficiency-driven metabolic changes of menopause (visceral fat accumulation, muscle loss, insulin resistance) while GLP-1 medications address the weight itself more directly. The combination produces synergistic benefits for women who need both. Coordination of these approaches is part of the clinical weight management discussion at Lapeer Women’s Health.
Our team at Lapeer Women’s Health discusses prescription weight loss approaches at both offices. No referral required.
Schedule a Gynecologic VisitEducational purposes only. Not medical advice. Content reviewed by Dr. Ramona D. Andrei, MD PhD FACOG.
Gynecologic care for women of every age
Lapeer Women’s Health — Rochester Hills
2710 S Rochester Rd, Suite 2
Rochester Hills, MI 48307
Serving patients in Lapeer, Rochester Hills, and surrounding communities throughout Southeast Michigan.